CLINICAL_TRIALS trial_result · 2021-07-16

Clinical Trial Update: A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) [Phase 3]

Phase 3 trial of ALKS 5461 for refractory major depressive disorder was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Alkermes, Inc. | Conditions: Refractory Major Depressive Disorder | Phase 3 | Status: TERMINATED | Results posted: 2021-07-16